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PHARMACY
New WHO Guide to Prevent and Control 
Cervical Cancer
Ale zehra, Clinical Pharmacist 
Cervical cancer is one of the world’s 
deadliest but most easily preventable forms 
of cancer for women, responsible for more 
than 270000 deaths annually, 85% of which 
occur in developing countries. An estimated 
one million-plus women worldwide are 
currently living with cervical cancer. On 3rd 
December 2014, the new “Comprehensive 
cervical cancer control”(also known as pink 
book) was launched by WHO. The new WHO 
guide provides a comprehensive cervical 
cancer control and prevention approach for 
governments and healthcare providers.
The main elements of the new guide are:
 l Vaccinate 9 to 13-year-old girls with two doses of Human    
  papillomavirus (HPV) vaccine to prevent infection with the HPV.   
  The reduced, 2-dose schedule has been shown to be as effective as the 
  current 3-dose schedule.
 l Use HPV tests to screen women for cervical cancer prevention. With   
  HPV testing, the frequency of screening will decrease. Once a woman 
  has been screened negative, she should not be rescreened for at least 5 
  years, but should be rescreened within 10. 
The new guide line identifi es key opportunities and ages throughout a woman’s 
life when cervical control and prevention can be put into action, especially for: 
 l Primary prevention: human papillomavirus (HPV) vaccination   
  targets girls aged 9 to 13 years, aiming to reach them before they 
  become sexually active.
 l Secondary prevention: access to technology for women over 30 years   
  of age, such as VIA (visual inspection of the cervix with acetic acid) 
  or HPV testing for screening, followed by treatment of detected 
  precancerous lesions, which may develop into cervical cancer.
 l Tertiary prevention: access to cancer treatment and management for   
  women of any age, including surgery, chemotherapy and radiotherapy.
 l When curative treatment is no longer an option, access to palliative   
  care is crucial.
Comprehensive
Cervical Cancer Control
A guide to essential practice 
Second edition
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Analgesic use in Adult Patients with Advanced Chronic Liver Disease 
or Cirrhosis
Dr. Hafsah M. Ashfaq, Pharmacist.
Patients with liver disease may develop acute or chronic pain from a variety of causes. In addition to causes common 
in the otherwise healthy population, those with advanced liver disease may have ascites (leading to abdominal and 
lower back pain) and gynecomastia (leading to mastalgia).
Management of pain in patients with liver disease raises special concerns. The choice of appropriate analgesic agents 
requires a thorough understanding of their pharmacokinetic and side effect profiles.
Altered Response and Pharmacokinetics Management Suggestions
Acetaminophen 
(Paracetamol)
Non-selective NSAIDs
Selective COX-2 
inhibitors
Fentanyl
Morphine
Tramadol
Glutathione tissues are reduced in 
individuals with cirrhosis, thereby 
lowering the dose threshold of 
acetaminophen that can be safely 
administered each day.
NSAIDs can decrease GFR and impair 
renal function in patients with advanced 
CLD or cirrhosis.
Excess cardiovascular events have been 
observed with this class of medications 
when used by patients without cirrhosis. 
Parent drug can accumulate after 
repeated dosing or when administered as 
a continuous infusion due to tissue and 
protein binding. 
Half-life can be increased by twofold. 
Accumulation of metabolites with 
complex effects can occur in patients 
with cirrhosis and renal failure. 
Unpredictable onset, variable analgesic 
efficacy, and risk of accumulation in 
patients with cirrhosis. 
l Acetaminophen is generally well   
 tolerated in patients with CLD or   
 cirrhosis, provided the total daily 
 dose is limited to no more than 2 g/
 day (4 tablets of 500mg/day)
l Also note that Paracetamol is 
 available in combination of other 
 pain killers and muscle relaxants 
 also so same caution should be 
 exercised in these products. E.g. 
 Nuberol, Nuberol Forte, Codogesic 
 etc. 
NSAIDs and aspirin should be avoided 
in patients with advanced CLD or 
cirrhosis. 
If used, Celecoxib product information 
suggests a 50% dose reduction for 
Child-Pugh class B cirrhosis. 
Generally a good choice for patients 
with CLD or cirrhosis when opiate 
treatment indicated. 
With repeated dosing, reduce dose and 
frequency by approx. 25-50%
Reduce dose and frequency by approx. 
50 % Avoid in patients with cirrhosis 
and renal failure as much as possible
 
Avoid use in patients with 
decompensated cirrhosis. 
A reduced dose of 25 mg every eight 
hours may be considered.
Non-opioid analgesics
Opioid analgesics (see NOTE)*
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Unpredictable analgesic efficacy and 
increased risk of toxicity in CLD or 
cirrhosis patients.
Not hepatically metabolized, dependent 
upon renal clearance.
Sedation and dizziness may limit 
usefulness in patients with advanced 
CLD or cirrhosis.
Not hepatically metabolized, dependent 
upon renal clearance.
Sedation and dizziness may limit 
usefulness in patients with advanced 
CLD or cirrhosis.
Accumulation of metabolites in 
hepatic impairment is less likely with 
Nortriptyline.
Carbamazepine has been associated 
with hepatotoxicity and serious allergic 
reactions 
Meperidine/Pethidine and Codeine 
should be avoided in such patients
Initiate treatment at 300 mg orally 
per day and gradually titrate dose. 
Maintenance dose is dependent upon 
renal function. 
Initiate treatment at 50 mg orally twice 
per day and gradually titrate dose.
Maintenance dose is dependent upon 
renal function.
Initiate treatment at 10 mg orally HS 
and gradually titrate dose 
Carbamazepine should be avoided 
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Altered Response and Pharmacokinetics Management Suggestions
Adjunctive agents for neuropathic pain
Meperidine (Pethidine), 
Codeine
Gabapentin
Pregabalin
Nortriptyline
Carbamazepine
* NOTE: All opioids can worsen or precipitate Hepatic Encephalopathy and should be used cautiously or 
avoided in patients with portal hypertension and preexisting Hepatic Encephalopathy
The Novel Treatment of Clostridium Difficile Associated Diarrhea 
(CDAD) 
Harris  Ahmed, Trainee Pharmacist
The emergence of Clostridium difficile associated disease (CDAD) is one of the important problems associ-
ated with widespread antibiotic use. Alteration of natural gut flora due to broad-spectrum antibiotic use leads 
to gut colonization by the aerobic, gram-positive, spore producing bacillus Clostridium difficile. C. difficile 
produces potent exotoxins that cause inflammatory, secretory diarrhea and colitis; in severe cases it may even 
lead to death. Any antibiotic may predispose to colonization by C. difficile, including Metronidazole and Van-
comycin, the two first line agents used to treat CDAD. Thus hospitals must have a solid antimicrobial steward-
ship program that ensures rational antibiotic use to minimize the growth, emergence and increasing virulence 
of C. difficile.
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Treatment of Clostridium Difficile
Initial Episode:  
                                
First relapse
Second relapse
Subsequent relapse
Studies of Rifaximin:
Fecal Microbiota Transplant 
(FMT):
Anion Binding Resins
Intravenous Immunoglobulin 
(IVIG)
Probiotics
Oral Metronidazole: 500 mg Q8H or 250 mg Q6H for 10 to 14 days
Oral Vancomycin: 125 mg orally Q6H for 10 to 14 days
Rectal Vancomycin: 500mg in 100ml NS Q6h + Metronidazole IV
Repeat treatment as in initial episode above. 
Alternative: Fidaxomicin1 200 mg orally q12h for 10 days
Tapering and pulsed oral Vancomycin :
125 mg PO Q6H for 7 to 14 days            125 mg PO Q12H for 7 days
125 mg PO QD for 7 days            125 mg PO every other day for 7 
days         125 mg PO QD every 3 days for 14 days.
Alternative: Fidaxomicin1 200 mg PO Q12H for 10 days
Fidaxomicin1 200 mg orally twice daily for 10 days if not used 
previously
Fecal bacteriotherapy (fecal microbiota transplant)
Consider anion binding resins with Vancomycin
Some studies have shown that sequential therapy with Vancomycin 
followed by Rifaximin may be effective for recurrent Clostridium 
difficile. However, exposure to rifamycins prior to development of 
CDI is a risk factor for rifampin-resistant C. difficile infection.
Single to multiple infusions of bacterial fecal flora originating from a 
healthy donor via a colonoscopy, an enema or a nasogastric tube
It’s used as an adjuvant 2-3 hours apart from Vancomycin. It 
neutralizes the exotoxins produced by C. difficile.
Example: Colestyramine, Colestipol1, Tolevamer1
It contains a C. difficile antitoxin and has been used in some patients 
with recurring CDI. Its effectiveness has not been properly elucidated
Effective in mild CDI
Antibiotic Therapy
Non- Antibiotic Therapy
1Not yet registered in Pakistan
Proton-Pump Inhibitors (PPIs) – Are we over using them?
Dr. Salwa Ahsan - Manager Inpatient Pharmacy
Proton-pump inhibitors (PPIs) remain the major evidence-based therapy for upper GI disorders, including 
GERD, dyspepsia, and peptic ulcer disease. The strong evidence supporting PPI efficacy and a favorable 
safety profile may have contributed to significant over-prescription, exposing patients to an increasing number 
of potential risks. 
 l In ambulatory care setting, the overutilization of PPIs is often a result of failure to re-assess the need  
  for continuation of therapy, or insufficient use of on-demand and step-down therapy. 
 l PPI overutilization in the inpatient setting is often a result of inappropriate stress ulcer prophylaxis  
  (SUP) in non-intensive care unit patients, and failure to discontinue SUP prior to hospital discharge. 
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Indication in Inpatient: 
From an inpatient perspective, appropriate initiation of PPI treatment would be limited to primary conditions 
requiring directed therapy such as undifferentiated upper GI bleed, duodenal or gastric ulcer, or erosive 
esophagitis] or a select population of intensive care unit (ICU) patients requiring prophylaxis.
Stress Ulcer Prophylaxis (SUP):
Prophylaxis is generally recommended in patients who are critically ill with risk factors for physiological 
stress-related bleeding, including respiratory failure, coagulopathy, sepsis, severe hypotension, acute renal 
failure, history of GI ulcer or a GI bleed within 1 year of admission, hepatic failure, major trauma, burns, 
spinal cord injury, organ transplantation, Glasgow Coma Score up to 10, surgery, high-dose corticosteroid 
therapy, renal failure, or ICU stay of at least 6 days. 
Patients receiving SUP should be assessed daily and when their risk factors resolve and clinical condition 
improves, discontinuation of SUP should be considered. Enteral nutrition may have prophylactic benefit in 
patients who are critically ill by optimizing splanchnic blood flow, enhancing secretion of cytoprotective 
prostaglandins, buffering acid, or other mechanisms – thus can be considered.
Discontinuation of SUP should also be considered when patients are transferred out from the ICU. Outside of 
the ICU, the only indications for initiation of PPI in the inpatient setting are GI diagnoses or conditions that 
warrant treatment.
Potential consequences of prolonged PPI therapy: 
This includes hypergastrinemia, enterochromaffin-like cell hyperplasia, and parietal cell hypertrophy, leading 
to rebound acid hypersecretion. 
PPIs have been linked via retrospective studies to increased risk of enteric infections including Clostridium 
difficile-associated diarrhea, community-acquired pneumonia, bone fracture, nutritional deficiencies (Vitamin 
B12 (cobalamin) deficiency), and possible interference with metabolism of antiplatelet agents. 
Reducing inappropriate prescribing of PPIs in the inpatient and outpatient settings can minimize potential for 
adverse events, and foster controllable cost expenditure.
Duration of therapy:
The Food and Drug Administration (FDA) advises that no more than three 14-day treatment courses should be 
used in one year in order to avoid side effects induced by PPI.
* As per manufacturer
**compounded oral solution is also available
Drugs IV PO1 Indication in 
Pediatrics*
Dosing Comments
Omeprazole**
Esomeprazole
Pantoprazole
40 mg
289/-
-
-
20 mg, 13.57/-
40 mg, 18.5/-
20 mg, 11.5/-
40 mg, 20/-
40 mg, 62/-
1 year and older
1 year and older
5 years and older
Once 
daily
Once 
daily
Once 
daily
Daily dosages of > 80 mg 
should be administered in 
divided doses
Twice daily for pathological 
Hypersecretory Conditions 
Including Zollinger-Ellison 
Syndrome
Available PPIs in AKUH Formulary with Price (per unit):
1administer 30 minutes before meal on empty stomach. Granules of capsule must not be crushed- use oral solution if to 
be given through NG tube.
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Characteristic Omeprazole Pantoprazole Esomeprazole
Bioavailability (%)
Time to peak plasma 
concentration (hours)
Plasma elimination half-life 
(hours)
Protein binding (%)
Urinary excretion of oral 
dose (%)
Duration of action (hours)
30 to 40
0.5 to 3.5
0.5 to 1.0
95
77
24
77
1.1 to 3.1
1.0 to 1.9
98
71 to 80
24
90% (repeated once-daily 
dosing) and 64% (single dose)
1.5
1 to 1.5
97
1
24
IV to PO Switch Guidelines
Drug & Poison Information Team
Introduction
IV to oral switch is the prompt conversion of IV antibiotic therapy to oral. Patients may be considered candi-
dates for switching from IV to oral therapy once the patient has shown clinical improvement and is medically 
stable.
Rationale
The majority of patients with a severe infection who are adequately absorbing oral medication and initially 
require IV therapy can be safely switched to oral therapy within 48 hours. There are a number of advantages 
to support the prompt switch from IV to oral therapy these are as follows 1,2,3:
l  Reduction in the likelihood of hospital acquired bacteraemia and infected/phlebitic IV lines.
l  Saves both medical and nursing time
l  Reduces discomfort for patients and enables improved mobility and the possibility of earlier hospital discharge.
l  Potential to significantly reduce treatment costs.
l  Patient is more likely to receive antibiotics at the correct time.
l  Potential reduction in the risk of adverse effects; errors in preparation are significantly higher with 
 parenteral drugs, compared to oral formulation.
Considerations for the early switch to oral therapy: COMS (review at 24-48 hours)
C Clinical improvement observed
O Oral route is not compromised (vomiting, malabsorptive disorder, swallowing problems, unconscious, 
severe diarrhea)
NB: if NG/PEG feeding then please consult your pharmacist for appropriate dosage form
M Markers showing a trend towards normal: Patient should be afebrile for the last 24 hours (Temp >360
C and <380 C) and DO NOT have more than one of the following, heart rate >90/min, resp rate >20/min, BP 
unstable, WBC<4 or >12 (WBC/neutrophils should show a trend towards normal); absence of such should not 
impede the switch if all other criteria are met and not neutropenic.
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The 7th Medication Safety Conference 2014, Abu Dhabi, UAE:  the best oral presentation award won by Ms. Farhat Zaheer (specialist, Compounding, IV admixture & Chemo section) and 
her team .Title of the project was “Strategies to enhance and reduce turnaround time of sterile and non-sterile compounding preparations for ambulatory care patients”   Approximately 
140 entries from 50 different countries were presented, while AKUH’s entry presented by Ms. Farhat Zaheer was declared the winner.  This was a quality improvement project related to 
process re-designing and innovative strategies that bring effi ciency and reduce turn around timings of sterile/non-sterile compounded medications for ambulatory care patients at AKUH.
Best Oral Presentation at 7th Medication Safety Conference, Abu Dhabi, UAE.
Proud to Report
S Specifi c indication/deep-seated infection (Prior to switch refer to table 1)
High risk/deep-seated infections
Certain infections may appear to respond promptly to intravenous therapy, but warrant prolonged IV therapy. 
This is to ensure that adequate drug levels are attained at the site of infection and to optimize the response and 
prevent relapse.
Discuss with Microbiology before switching patients with a high risk/deep seated infection to oral therapy.
Deep seated infections that may require an initial 
2 weeks of IV therapy
l  Liver abscess
l  Osteomyelitis, Septic arthritis
(N.B. high-dose oral Clindamycin may be    
appropriate once patient is stable)
l  Empyema
l  Cavitating pneumonia
High risk infections requiring prolonged IV 
therapy
l Staphylococcus aureus bacteraemia
l Severe necrotizing soft tissue infections
l Severe infections during chemotherapy 
 related neutropenia
l Infected implants/prosthesis
l Meningitis/encephalitis
l Intracranial abscesses
l Mediastinitis
l Endocarditis
l Exacerbation of cystic fi brosis/bronchiectasis
l Inadequately drained abscesses or empyema
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The Aga Khan University Hospital, Karachi
Department of Pharmacy Services at the AKUH celebrated World Pharmacist Day( cake cutting + symposium+ stall) in collaboration with the 
Society of Hospital Pharmacists of Pakistan and Hospital Pharmacy Section of FIP-International Pharmaceutical Federation based in Hague, The 
Netherlands. Such platform identifi es the contributions of pharmacist along with other health care professionals in developing a better health and 
ultimately bringing better quality to life.
25th September, World Pharmacist Day-Celebration
